Inotec AMD Secures £3.4m Towards Series C Funding from Wealth Club

Inotec AMD is delighted to have secured Wealth Club investment towards their Series C funding. This investment will allow the organisation to drive the adoption of NATROX® Oxygen Wound Therapy within targeted countries in need of this revolutionary new technology. Bringing topical oxygen therapy to the forefront of clinicians’ minds when reviewing non-healing wounds is a key commercial strategy.

Craig Kennedy, CEO of Inotec AMD, commented, “The Wealth Club is a forward-thinking investment group whose funding will provide us with a fantastic opportunity to further drive clinical adoption of the NATROX® Oxygen Wound Therapy in our key markets. They have been a great group to work with and we are extremely pleased to have them on board”.